Sarepta Therapeutics, Inc. (0L35.L)
USD 122.56
(-2.47%)
USD 122.56
(-2.47%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.13 Billion USD | -29.3% |
| 2022 | 1.6 Billion USD | 40.71% |
| 2021 | 1.13 Billion USD | 6.11% |
| 2020 | 1.07 Billion USD | 47.04% |
| 2019 | 729.62 Million USD | 73.49% |
| 2018 | 420.55 Million USD | -1.02% |
| 2017 | 424.87 Million USD | 6932.04% |
| 2016 | 6.04 Million USD | -59.64% |
| 2015 | 14.96 Million USD | 300.45% |
| 2014 | 3.73 Million USD | 137.18% |
| 2013 | 1.57 Million USD | -5.52% |
| 2012 | 1.66 Million USD | -5.07% |
| 2011 | 1.75 Million USD | -4.61% |
| 2010 | 1.84 Million USD | -4.26% |
| 2009 | 1.92 Million USD | -3.84% |
| 2008 | 2 Million USD | -3.38% |
| 2007 | 2.07 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.13 Billion USD | 0.1% |
| 2024 Q2 | 1.13 Billion USD | 0.1% |
| 2023 Q1 | 1.28 Billion USD | -19.58% |
| 2023 FY | 1.13 Billion USD | -29.3% |
| 2023 Q4 | 1.13 Billion USD | -17.43% |
| 2023 Q3 | 1.37 Billion USD | 0.5% |
| 2023 Q2 | 1.36 Billion USD | 5.94% |
| 2022 Q2 | 1.14 Billion USD | 0.24% |
| 2022 Q3 | 1.57 Billion USD | 38.39% |
| 2022 Q4 | 1.6 Billion USD | 1.51% |
| 2022 FY | 1.6 Billion USD | 40.71% |
| 2022 Q1 | 1.13 Billion USD | -0.08% |
| 2021 Q4 | 1.13 Billion USD | -1.72% |
| 2021 Q1 | 1.15 Billion USD | 7.36% |
| 2021 Q2 | 1.15 Billion USD | 0.56% |
| 2021 Q3 | 1.15 Billion USD | 0.01% |
| 2021 FY | 1.13 Billion USD | 6.11% |
| 2020 Q3 | 768.69 Million USD | 0.28% |
| 2020 FY | 1.07 Billion USD | 47.04% |
| 2020 Q2 | 766.55 Million USD | 1.77% |
| 2020 Q4 | 1.07 Billion USD | 39.57% |
| 2020 Q1 | 753.21 Million USD | 3.23% |
| 2019 FY | 729.62 Million USD | 73.49% |
| 2019 Q2 | 481.24 Million USD | 0.7% |
| 2019 Q3 | 486.16 Million USD | 1.02% |
| 2019 Q4 | 729.62 Million USD | 50.08% |
| 2019 Q1 | 477.91 Million USD | 13.64% |
| 2018 FY | 420.55 Million USD | -1.02% |
| 2018 Q2 | 429.92 Million USD | 0.6% |
| 2018 Q1 | 427.36 Million USD | 0.59% |
| 2018 Q3 | 415.44 Million USD | -3.37% |
| 2018 Q4 | 420.55 Million USD | 1.23% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q1 | 2.34 Million USD | -61.22% |
| 2017 FY | 424.87 Million USD | 6932.04% |
| 2017 Q4 | 424.87 Million USD | 1500.29% |
| 2017 Q3 | 26.55 Million USD | 0.0% |
| 2016 Q1 | 13.37 Million USD | -10.66% |
| 2016 Q2 | 10.11 Million USD | -24.39% |
| 2016 Q3 | 8.49 Million USD | -16.02% |
| 2016 FY | 6.04 Million USD | -59.64% |
| 2016 Q4 | 6.04 Million USD | -28.84% |
| 2015 FY | 14.96 Million USD | 300.45% |
| 2015 Q3 | 17.39 Million USD | -15.76% |
| 2015 Q2 | 20.65 Million USD | 1324.28% |
| 2015 Q1 | 1.45 Million USD | -61.21% |
| 2015 Q4 | 14.96 Million USD | -13.96% |
| 2014 FY | 3.73 Million USD | 137.18% |
| 2014 Q2 | 1.52 Million USD | -1.68% |
| 2014 Q3 | 3.76 Million USD | 146.75% |
| 2014 Q4 | 3.73 Million USD | -0.66% |
| 2014 Q1 | 1.55 Million USD | -1.59% |
| 2013 FY | 1.57 Million USD | -5.52% |
| 2013 Q3 | 1.59 Million USD | -1.42% |
| 2013 Q2 | 1.62 Million USD | -1.4% |
| 2013 Q1 | 1.64 Million USD | -1.38% |
| 2013 Q4 | 1.57 Million USD | -1.44% |
| 2012 Q4 | 1.66 Million USD | -1.3% |
| 2012 Q3 | 1.69 Million USD | -1.34% |
| 2012 Q2 | 1.71 Million USD | -1.27% |
| 2012 Q1 | 1.73 Million USD | -1.25% |
| 2012 FY | 1.66 Million USD | -5.07% |
| 2011 Q1 | 1.82 Million USD | -1.14% |
| 2011 Q2 | 1.8 Million USD | -1.15% |
| 2011 Q3 | 1.77 Million USD | -1.22% |
| 2011 Q4 | 1.75 Million USD | -1.18% |
| 2011 FY | 1.75 Million USD | -4.61% |
| 2010 Q1 | 3.01 Million USD | 56.5% |
| 2010 FY | 1.84 Million USD | -4.26% |
| 2010 Q3 | 1.86 Million USD | -1.06% |
| 2010 Q4 | 1.84 Million USD | -1.13% |
| 2010 Q2 | 1.88 Million USD | -37.46% |
| 2009 Q3 | 1.95 Million USD | -23.26% |
| 2009 Q4 | 1.92 Million USD | -1.33% |
| 2009 Q2 | 2.54 Million USD | 1.19% |
| 2009 Q1 | 2.51 Million USD | 25.5% |
| 2009 FY | 1.92 Million USD | -3.84% |
| 2008 Q2 | 2.03 Million USD | -3.07% |
| 2008 Q1 | 2.09 Million USD | 1.34% |
| 2008 Q4 | 2 Million USD | -0.71% |
| 2008 Q3 | 2.01 Million USD | -0.92% |
| 2008 FY | 2 Million USD | -3.38% |
| 2007 Q2 | 2.1 Million USD | 0.0% |
| 2007 Q4 | 2.07 Million USD | -0.87% |
| 2007 FY | 2.07 Million USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | 2.08 Million USD | -0.85% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -4546.787% |
| Dynavax Technologies Corporation | 252.41 Million USD | -348.666% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -3311.601% |
| Perrigo Company plc | 3.63 Billion USD | 68.825% |
| Illumina, Inc. | 1.48 Billion USD | 23.941% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 96.383% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -113151.5% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 85.921% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 91.258% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -551.796% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 58.1% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -4711.228% |
| Waters Corporation | 2.3 Billion USD | 50.878% |
| Biogen Inc. | 7.18 Billion USD | 84.245% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -3279.129% |
| Evolus, Inc. | 120.35 Million USD | -840.947% |
| Adicet Bio, Inc. | 17.7 Million USD | -6297.306% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -2954.33% |
| bluebird bio, Inc. | 224.41 Million USD | -404.643% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -125.805% |
| FibroGen, Inc. | 89.69 Million USD | -1162.601% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 58.592% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -34868.942% |
| Homology Medicines, Inc. | 43.17 Million USD | -2523.02% |
| Geron Corporation | 35.05 Million USD | -3131.049% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 51.664% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -191.992% |
| Myriad Genetics, Inc. | 130.9 Million USD | -765.176% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -120895.192% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -1070.594% |
| Zoetis Inc. | 6.56 Billion USD | 82.747% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -25627.283% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 42.673% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -90.95% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -56.274% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -3212.416% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 19.128% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -2378.531% |
| Verastem, Inc. | 40.08 Million USD | -2725.213% |
| Nektar Therapeutics | 112.62 Million USD | -905.563% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -535.994% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -36741.737% |
| OPKO Health, Inc. | 222.03 Million USD | -410.064% |
| Exelixis, Inc. | 189.94 Million USD | -496.236% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -338.449% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -770.73% |
| Imunon, Inc. | 1.13 Million USD | -99305.07% |
| Blueprint Medicines Corporation | 610.96 Million USD | -85.366% |
| Insmed Incorporated | 1.19 Billion USD | 5.098% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 24.461% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1887.287% |
| TG Therapeutics, Inc. | 100.11 Million USD | -1031.18% |
| Incyte Corporation | 29.16 Million USD | -3783.53% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -153.643% |